Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Tyler EM, Jungbluth AA, O'Reilly RJ, Koehne G.

Blood. 2013 Jan 10;121(2):308-17. doi: 10.1182/blood-2012-06-435040. Epub 2012 Nov 16.

2.

Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.

Ishikawa T, Fujii N, Imada M, Aoe M, Meguri Y, Inomata T, Nakashima H, Fujii K, Yoshida S, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M.

Cytotherapy. 2017 Apr;19(4):514-520. doi: 10.1016/j.jcyt.2016.12.007. Epub 2017 Jan 27.

PMID:
28139337
3.

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.

Leukemia. 2013 Mar;27(3):642-9. doi: 10.1038/leu.2012.277. Epub 2012 Oct 1.

5.

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.

Blood. 2001 Aug 15;98(4):934-9.

6.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM.

Leukemia. 2013 Jul;27(7):1538-47. doi: 10.1038/leu.2013.66. Epub 2013 Mar 1.

7.

Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation.

Morita Y, Heike Y, Kawakami M, Miura O, Nakatsuka S, Ebisawa M, Mori S, Tanosaki R, Fukuda T, Kim SW, Tobinai K, Takaue Y.

Int J Cancer. 2006 Sep 15;119(6):1360-7.

8.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

9.

Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.

Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M.

Int J Cancer. 2016 Apr 1;138(7):1792-801. doi: 10.1002/ijc.29909. Epub 2015 Nov 27.

11.

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.

Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K.

Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65.

12.

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD.

Sci Transl Med. 2013 Feb 27;5(174):174ra27. doi: 10.1126/scitranslmed.3004916.

13.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ.

Biol Blood Marrow Transplant. 2003 May;9(5):312-9.

14.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP 3rd, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J.

Haematologica. 2016 Oct;101(10):1251-1259. Epub 2016 Jun 27.

15.

Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.

Tyler EM, Jungbluth AA, Gnjatic S, O'Reilly RJ, Koehne G.

Cancer Immunol Res. 2014 Jun;2(6):547-58. doi: 10.1158/2326-6066.CIR-13-0174. Epub 2014 Mar 3.

17.

Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.

Wei L, Zuo H, Sun X, Liu T, Guo M, Liu G, Sun Q, Qiao J, Wang D, Yu C, Hu K, Dong Z, Ai H.

Int J Hematol. 2010 May;91(4):652-60. doi: 10.1007/s12185-010-0551-7. Epub 2010 Apr 8.

PMID:
20376582
18.
19.

Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.

Bornhäuser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Hölig K, Radke J, Tuve S, Wermke M, Wehner R, Jähnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M.

Blood. 2011 Jun 30;117(26):7174-84. doi: 10.1182/blood-2010-09-308569. Epub 2011 May 3.

20.

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.

Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R.

Blood. 1995 Dec 1;86(11):4337-43.

Supplemental Content

Support Center